PSMD14 and glioblastoma: In translational medicine, the PSMD14 inhibitor, Thiolutin, curbed GBM progression <i>in vitro</i> and <i>in vivo</i> by disrupting the <i>de novo</i> purine biosynthesis and resulting in mitochondrial fragmentation.